Aequus Pharmaceuticals Inc. announced the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada. The manufacturer, Medicom Healthcare (UK), is in the process of changing its MDSAP provider. The switch was necessitated by the existing Notified Body being unable to offer all relevant global certifications.

Until this process is completed, Aequus Pharmaceuticals will pause sales of the class leading Evolve® range of products in the Canadian market. The company look forward to Evolve® returning to patients in Canada as soon as MDSAP Certification is issued. Aequus and Medicom Healthcare assure valued customers and eyecare professionals that the Evolve® Intensive eyedrops and gel will return to the Canadian market soon.

The Company remains steadfast in its commitment to delivering innovative solutions that enhance the well-being of patients across Canada.